Glenmark launches Empagliflozin in India under Glempa brand

Posted by on



Glenmark Pharmaceuticals announced on Wednesday the launch of a new medication for glycemic control and weight loss in diabetes patients. The Mumbai-based company introduced Empagliflozin, a well-known SGLT2 inhibitor, under the brand name Glempa.

Comments

Post a Comment